Didn't catch our #JPM26 presentation? Catch the video we presented here "Either you were in the M&A basket and public markets investors thought you were going to get bought by Big Pharma and your stock traded well, or you weren't...[but] it's great to be in an environment where

Until you had this opportunity for companies to "graduate", what it felt like to be a public biopharma CEO...either you were in the M&A basket and public markets investors thought you were going to get bought by Big Pharma and your stock traded well, or you weren't... [but] *it's

Join us at @jpmorgan's 44th Annual Healthcare Conference where our CEO @gline will take center stage to discuss Roivant’s strong track record, upcoming developments and what’s ahead in 2026 and beyond. #JPM2026

Curious about how we’re continuing to evolve at Roivant? Check out the @Biotech2050Pod featuring our CEO, @gline, to learn how we're approaching development: https://t.co/UaP2EbCUk5

We had a packed house for our recent Investor Day where we highlighted continued pipeline progress and our outlook for the next phase of growth while maintaining our unique culture, dynamism and focus on shareholder value creation. Review our presentation: https://t.co/mOBWcA4kl6

Ben Zimmer @priovanttx discusses the company's experimental targeted therapy to treat the rare autoimmune condition dermatomyositis and how its relationship with its parent @Roivant frees it from reliance on the capital markets. @GlobalGenes #RARECast https://t.co/vxYI3Rmbof

Uncontrolled Graves’ disease can lead to serious health complications including eye inflammation and swollen, bulging eyes. We believe in FcRN-targeted therapies that may help reframe care for people living with Graves’ disease. Learn more: https://t.co/GP8xSz96Ru #GravesDisease

𝐉𝐞𝐟𝐟𝐞𝐫𝐢𝐞𝐬 𝐋𝐨𝐧𝐝𝐨𝐧: Catching up with @Roivant CEO @gline at the @Jefferies Global Healthcare Conference in London. $ROIV

Today, we reported our Q2 financial results. Find key highlights here: https://t.co/Nk5KU34kHb

We were honored with the Double Helix Award at @LS_Cares’ Impact Night! Thank you Life Science Cares New York for helping us be on the frontlines making a difference for patients and communities in need.

Graves’ disease, an autoimmune disease, disproportionately impacts women. Learn how Immunovant is applying a patient-focused approach to help advance treatment for people living with this condition: https://t.co/UecNjdjQ1v #GravesDisease

Graves' Disease causes an overactive thyroid and hyperthyroidism, with symptoms like nervousness, anxiety, and more. See how we strive to meet the complex and variable needs of people with Graves’ disease through our latest research: https://t.co/zHcHW33KMX #GravesDisease

#NEWS: Along with Priovant Therapeutics, we announced positive results from the Phase 3 VALOR study evaluating our inflammatory disease prospect in dermatomyositis (DM). Learn more about this exciting moment for the DM community: https://t.co/ypykGI8cxP

This morning, Roivant and Priovant announced positive Phase 3 VALOR study results for brepocitinib in dermatomyositis - find the press release with more details here

We’re thrilled to be recognized as a 2025 Best Workplace in BioPharma™. This recognition demonstrates Roivant’s commitment to building a high-performance and talent-oriented culture. Learn about this achievement:  https://t.co/uaMpVhJ4Dl  #BestWorkplaces #GPTWCertified

https://t.co/DdWlEp37S0

https://t.co/ZhANFvpGAe

✔️Of the 17 responders to therapy, ~50% (8/17) achieved anti-thyroid drug (ATD) free remission at six months following end of batoclimab treatment